Zayed Sustainability Prize 2023 Demonstrates Global Reach and Impact with over 4,500 Submissions
15.9.2022 03:27:00 EEST | Business Wire | Press release
Following a successful 4-month submissions phase, the Zayed Sustainability Prize, the UAE's pioneering global award for recognising excellence in sustainability, has officially closed entries for its 2023 awards cycle. Over 4,500 applications were received across the five Prize categories of Health, Food, Energy, Water and Global High Schools, from a record 152 countries, demonstrating the Prize’s growing global reach and impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005418/en/
The Zayed Sustainability Prize 2023 receives more than 4,500 submissions globally (Graphic: AETOSWire)
The Zayed Sustainability Prize winners will be announced at the 2023 Zayed Sustainability Prize Awards Ceremony that will be held on January 16, 2023 as part of Abu Dhabi Sustainability Week.
The Prize witnessed a 13% increase in submissions compared to last year from small and medium-sized enterprises (SMEs), nonprofit organisations and high schools. Total submissions from SMEs increased across all categories, underscoring a rising trend that SMEs are putting sustainability at the top of their agenda.
H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Prize, said: “For the last 14 years the Zayed Sustainability Prize has incentivised practical solutions to global challenges that deliver tangible impact at a community level around the world. Inspired by the commitment to sustainable development and humanitarian legacy of Sheikh Zayed bin Sultan Al Nahyan, the Prize has improved the lives of 370 million people in 151 countries to date. This year, we have seen applications from a record number of countries across every category from health, food, energy, water and global high schools. I'm excited to see what creative solutions this year’s applicants will bring to the table, particularly as the UAE prepares to host COP 28 next year.”
“Given that we want to leverage COP 28 as a platform for inclusivity and practical outcomes, I am confident that the Prize can help to deliver social and economic progress from across the private sector, small business community and an increasingly active and engaged younger generation,” he added.
This year’s submissions were more diverse than ever before, revealing climate change’s impact on every country across every continent, and reflecting a growing awareness that urgent climate action is critical to meet global net zero carbon goals by mid-century.
More submissions received this year came from developing nations in Sub-Saharan Africa, South Asia, East Asia, Latin America, the Middle East, and North Africa, which is an important indication of the growing participation of developing countries in the fight against climate change.
The top submitting countries included Kenya, India, China, Egypt, Brazil and the United States. By receiving submissions from a wide range of geographies, the Prize is better equipped to deliver on its mission of driving impactful, innovative, and inspiring sustainable and humanitarian development around the world.
The Food (1,426) and Health (946) categories attracted the greatest number of submissions, followed by Energy (736) and Water (601), while the Global High Schools category received 829 submissions.
In the Food category, which received nearly 20% increase in submissions compared to last year, many entries presented solutions aimed at achieving sustainable food production to address rising food insecurity and malnutrition in a world threatened by climate change.
In the Health category, several entries address the weaknesses of the healthcare systems exposed by the Covid-19 pandemic, and offer solutions that provide more resilient, inclusive, accessible, and sustainable healthcare services to people most in need.
In the Energy category, the Prize received numerous entries focused on improving sustainable energy access in vulnerable communities, supporting United Nations Sustainable Development Goal 7, affordable and clean energy for all, and driving the low-carbon energy transition.
Finally, in the Water category, a number of entries offered solutions aimed at addressing the clean water production, climate change, and water resource management challenges faced around the world, and particularly in developing nations.
The number of submissions received from high schools grew by 55% compared to last year, which is especially encouraging and a testament to young people’s growing awareness of the challenges and risks presented by the climate crisis and of the opportunity to lead on sustainable development. Entries in the Global High Schools category proposed waste management solutions, clean energy systems, and food systems like hydroponics and aquaponics, reflecting the students’ innovative thinking and careful consideration of projects most suited for their local communities.
Following the close of submissions, the Prize now enters the evaluation stage. All entries will now be shortlisted by an independent research and analysis consultancy. A Selection Committee comprised of globally renowned industry experts will then assess the qualified entries and shortlist the candidates. The third and final tier of the evaluation process is the Jury, which will convene in October, to unanimously elect the winners in each category.
Since its launch in 2008, the US$3 million Prize has, directly and indirectly, transformed the lives of over 370 million people around the world. Its global impact continues to grow, as it further catalyses humanitarian outreach and sustainable development. Each winner in the Health, Food, Energy, and Water categories receive US$600,000 to expand the scope and scale of their sustainability solution(s), while the Global High Schools category has six winners, representing six world regions, with each winner receiving up to US$100,000.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005418/en/
Contact information
Baha Haroun
Baha.haroun@bcw-global.com
Reem Diab
Reem.Diab@bcw-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
